These data suggest that the 75-mg dose of alirocumab sc. Q2W may be appropriate for adequate lowering of LDL-C in a large portion of patients with primary hypercholesterolemia at moderate CV risk who are not receiving statin therapy. In addition, the safety profile continues to show good tolerability and appears comparable to that of ezetimibe in this study. Alirocumab self-injected sc. Q2W appears to be a viable option for lowering LDL-C in patients unable or unwilling to utilize statin therapy. An uptitration plan based on LDL-C response appears to be feasible and may be useful in future clinical practice. Alirocumab significantly lowers LDL-C to a much greater degree than ezetimibe, which is a commonly prescribed lipid-lowering medicine.
In addition to the peer-review process, with the author(s) consent, the manufacturer of the product(s) discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made at the discretion of the author(s) and based on scientific or editorial merit only.
Future Cardiol. 2015;11(1):27-37. © 2015 Future Medicine Ltd.